COVID-19 Human Challenge Trials – What will be the Regulatory Considerations?
Join SGS experts and explore the potential of CHIM, COVID-19 regulatory considerations, working with regulators and how to accelerate your pipeline.
28 Apr 2020, 12:00
28 Apr 2020, 13:00
The current SARS-Cov-2 pandemic has brought the world to a standstill. Research groups and drug developers all over the world are scrambling to develop antivirals and vaccines to treat or prevent COVID-19. Longer term, better modeling will be required to test compounds in a controlled clinical setting once the pandemic has abated. Such a model could be a human challenge trial, commonly known as a controlled human infection model, or CHIM.
A coronavirus CHIM could be an ideal tool to support endeavors to develop effective COVID-19 interventions and provide a longer-term platform to support preparations against the emergence of new or novel coronaviruses.
This webinar will highlight the regulatory considerations to implement such a model and speed up the development pathway of much needed drugs and antiviral products.
- Introduction to controlled human infection modeling (CHIM)
- SARS-CoV-2: an introduction
- Regulatory considerations surrounding COVID-19 modeling
- Working with regulators on COVID-19 CHIM design and development
- How a COVID-19 CHIM trial could accelerate your pipeline development
Cost: No Charge
Can't Make a Live Session?
For further information, please contact:
SGS United Kingdom Ltd
t: +44 (0) 151 350 6666